Paper26330427
New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.
Lim J and 2 others. Clin Cancer Res, 2015. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype. Papers, record 26330427. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26330427
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sarcoma | Major topic |
| Animals | |
| Epigenesis, Genetic | |
| Genomics | |
| Histone Deacetylase Inhibitors | |
| Humans | |
| Immunotherapy | |
| Molecular Diagnostic Techniques | |
| Precision Medicine |
Source PubMed
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41872897 | Multicenter peritumoral radiomics in oncology: advances, challenges, and future directions. | Radiat Oncol | 2026 | https://conductscience.org/library/papers/41872897 | PubMed |
| 41448855 | Periostin Promotes Sarcoma Growth by Promoting Tumor-Associated Macrophage Migration and Differentiation. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/41448855 | PubMed |
| 39737219 | Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial. | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/39737219 | PubMed |
| 38868205 | Sarcoma_CellminerCDB: A tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines. | iScience | 2024 | https://conductscience.org/library/papers/38868205 | PubMed |
| 36438917 | Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence. | Int J Med Sci | 2022 | https://conductscience.org/library/papers/36438917 | PubMed |
| 36433954 | circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment. | Nat Commun | 2022 | https://conductscience.org/library/papers/36433954 | PubMed |
| 34925348 | Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. | Front Immunol | 2021 | https://conductscience.org/library/papers/34925348 | PubMed |
| 34299136 | Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34299136 | PubMed |
| 34201149 | Sarcoma Metabolomics: Current Horizons and Future Perspectives. | Cells | 2021 | https://conductscience.org/library/papers/34201149 | PubMed |
| 33388091 | Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes. | Hereditas | 2021 | https://conductscience.org/library/papers/33388091 | PubMed |
| 32977646 | Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32977646 | PubMed |
| 32503133 | Glycogen Synthase Kinase 3β in Cancer Biology and Treatment. | Cells | 2020 | https://conductscience.org/library/papers/32503133 | PubMed |
| 31988250 | TGFβ and Hippo Pathways Cooperate to Enhance Sarcomagenesis and Metastasis through the Hyaluronan-Mediated Motility Receptor (HMMR). | Mol Cancer Res | 2020 | https://conductscience.org/library/papers/31988250 | PubMed |
| 30545340 | The changing landscape of phase II/III metastatic sarcoma clinical trials-analysis of ClinicalTrials.gov. | BMC Cancer | 2018 | https://conductscience.org/library/papers/30545340 | PubMed |
| 30249211 | Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. | BMC Cancer | 2018 | https://conductscience.org/library/papers/30249211 | PubMed |
| 29490948 | YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis. | Cancer Res | 2018 | https://conductscience.org/library/papers/29490948 | PubMed |
| 29351847 | Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. | Mol Cell | 2018 | https://conductscience.org/library/papers/29351847 | PubMed |
| 29308311 | Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. | Oncoimmunology | 2018 | https://conductscience.org/library/papers/29308311 | PubMed |
| 29308306 | Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. | Oncoimmunology | 2018 | https://conductscience.org/library/papers/29308306 | PubMed |
| 28656259 | Anti-angiogenesis target therapy for advanced osteosarcoma (Review). | Oncol Rep | 2017 | https://conductscience.org/library/papers/28656259 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26330427
GET https://conductscience.org/api/papers/v1/26330427/cited_by?page=2